G-Protein-Coupled Receptors as Drug Targets

Enzyme Inhibition in Drug Discovery and Development: The Good and the Bad

Volumn , Issue , 2010, Pages 625-667

  Miao, Wenyan ^a   Wu, Lijun ^b  

^a PFIZER INC   (United States)

^b Resolvyx Pharmaceuticals Inc   (United States)

Author keywords

G protein coupled receptors as drug targets; GPCRs as drug targets in inflammation; Obesity and GPCRs drug targets

Indexed keywords

EID: 84884426509     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470538951.ch20     Document Type: Chapter

References (173)

1. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 1985; 89 (5): 1070-1077.
2. Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006; 6 (4): 383-394.
3. Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007; 25: 787-820.
4. Arbour N, Tremblay P, Oth D. N-Formyl-methionyl-leucyl-phenylalanine induces and modulates IL-1 and IL-6 in human PBMC. Cytokine 1996; 8 (6): 468-475.
5. Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA, Kasuga M. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003; 52 (7): 947-952.
6. Ashton JC. Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs 2007; 8 (5): 373-384.
7. Aung HT, Schroder K, Himes SR, Brion K, van Zuylen W, Trieu A, Suzuki H, Hayashizaki Y, Hume DA, Sweet MJ, Ravasi T. LPS regulates proinflammatory gene expression in macrophages by altering histone deacetylase expression. FASEB J 2006; 20 (9): 1315-1327.
8. Back M, Hansson GK. Leukotriene receptors in atherosclerosis. Ann Med 2006; 38 (7): 493-502.
9. Bansal G, Druey KM, Xie Z. R4 RGS proteins: regulation of G-protein signaling and beyond. Pharmacol Ther 2007; 116 (3): 473-495.
10. Baraf HS. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr Pharm Des 2007; 13 (22): 2228-2236.
11. Barnes MJ, Holmes G, Primeaux SD, York DA, Bray GA. Increased expression of mu opioid receptors in animals susceptible to diet-induced obesity. Peptides 2006; 27 (12): 3292-3298.
12. Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, Brynes AE, Low MJ, Ghatei MA, Cone RD, Bloom SR. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002; 418 (6898): 650-654.
13. Beck B, Richy S, Dimitrov T, Stricker-Krongrad A. Opposite regulation of hypothalamic orexin and neuropeptide Y receptors and peptide expressions in obese Zucker rats. Biochem Biophys Res Commun 2001; 286 (3): 518-523.
14. Bilkei-Gorzo A, Abo-Salem OM, Hayallah AM, Michel K, Muller CE, Zimmer A. Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol 2008; 377 (1): 65-76.
15. Bina KG, Cincotta AH. Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology 2000; 71 (1): 68-78.
16. Blandizzi C. Enteric alpha-2 adrenoceptors: pathophysiological implications in functional and inflammatory bowel disorders. Neurochem Int 2007; 51 (5): 282-288.
17. Bourne HR. How receptors talk to trimeric G proteins. Curr Opin Cell Biol 1997; 9 (2): 134-142.
18. Bouwknecht JA, van der Gugten J, Hijzen TH, Maes RA, Hen R, Olivier B. Male and female 5-HT(1B) receptor knockout mice have higher body weights than wildtypes. Physiol Behav 2001; 74 (4-5): 507-516.
19. Braquet P, Touqui L, Shen TY, Vargaftig BB. Perspectives in platelet-activating factor research. Pharmacol Rev 1987; 39 (2): 97-145.
20. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008; 153 (2): 309-318.
21. Bunnett NW. Protease-activated receptors: how proteases signal to cells to cause inflammation and pain. Semin Thromb Hemost 2006; 32 (Suppl 1): 39-48.
22. Burnstock G. Introduction: P2 receptors. Curr Top Med Chem 2004; 4 (8): 793-803.
23. Butler AA, Cone RD. The melanocortin receptors: lessons from knockout models. Neuropeptides 2002; 36 (2-3): 77-84.
24. Casale TB, Wood D, Richerson HB, Trapp S, Metzger WJ, Zavala D, Hunninghake GW. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest 1987; 79 (4): 1197-1203.
25. Catania A, Gatti S, Colombo G, Lipton JM. Targeting melanocortin receptors as a novel strategy to control inflammation. Pharmacol Rev 2004; 56 (1): 1-29.
26. Cavaillon JM, Fitting C, Haeffner-Cavaillon N. Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide-stimulated monocytes and macrophages. Eur J Immunol 1990; 20 (2): 253-257.
27. Charo IF, Peters W. Chemokine receptor 2 (CCR2) in atherosclerosis, infectious diseases, and regulation of T-cell polarization. Microcirculation 2003; 10 (3-4): 259-264.
28. Chiba K, Matsuyuki H, Maeda Y, Sugahara K. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 2006; 3 (1): 11-19.
29. Chung S, Funakoshi T, Civelli O. Orphan GPCR research. Br J Pharmacol 2008; 153 (Suppl 1): S339-S346.
30. Cocks TM, Fong B, Chow JM, Anderson GP, Frauman AG, Goldie RG, Henry PJ, Carr MJ, Hamilton JR, Moffatt JD. A protective role for protease-activated receptors in the airways. Nature 1999; 398 (6723): 156-160.
31. Coelho AM, Ossovskaya V, Bunnett NW. Proteinase-activated receptor-2: physiological and pathophysiological roles. Curr Med Chem Cardiovasc Hematol Agents 2003; 1 (1): 61-72.
32. Coll AP, Farooqi IS, Challis BG, Yeo GS, O'Rahilly S. Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 2004; 89 (6): 2557-2562.
33. Communi D, Parmentier M, Boeynaems JM. Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun 1996; 222 (2): 303-308.
34. Communi D, Gonzalez NS, Detheux M, Brezillon S, Lannoy V, Parmentier M, Boeynaems JM. Identification of a novel human ADP receptor coupled to G(i). J Biol Chem 2001; 276 (44): 41479-41485.
35. Copeland KF. Inhibition of HIV-1 entry into cells. Recent Patents Anti-Infect Drug Disc 2006; 1 (1): 107-112.
36. Cressman VL, Lazarowski E, Homolya L, Boucher RC, Koller BH, Grubb BR. Effect of loss of P2Y(2) receptor gene expression on nucleotide regulation of murine epithelial Cl(-) transport. J Biol Chem 1999; 274 (37): 26461-26468.
37. Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP, Purnell JQ. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002; 346 (21): 1623-1630.
38. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2- adrenergic receptor to different G proteins by protein kinase A. Nature 1997; 390 (6655): 88-91.
39. Deupi X, Dolker N, Lopez-Rodriguez ML, Campillo M, Ballesteros JA, Pardo L. Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. Curr Top Med Chem 2007; 7 (10): 991-998.
40. DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol 2007; 69: 483-510.
41. Dhanasekaran N, Dermott JM. Signaling by the G12 class of G proteins. Cell Signal 1996; 8 (4): 235-245.
42. Duvernay MT, Filipeanu CM, Wu G. The regulatory mechanisms of export trafficking of G protein-coupled receptors. Cell Signal 2005; 17 (12): 1457-1465.
43. Ebeling C, Lam T, Gordon JR, Hollenberg MD, Vliagoftis H. Proteinase-activated receptor-2 promotes allergic sensitization to an inhaled antigen through a TNF-mediated pathway. J Immunol 2007; 179 (5): 2910-2917.
44. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G. Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and-independent coordinated alterations of receptor localization and function. J Biol Chem 2006; 281 (50): 38812-38824.
45. Farooqi IS. Monogenic human obesity syndromes. Prog Brain Res 2006; 153: 119-125. Ferguson SS. Phosphorylation-independent attenuation of GPCR signalling. Trends Pharmacol Sci 2007; 28 (4): 173-179.
46. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJ, Hunter GD, McLean JS, McGarry F, Ramage R, Jiang L, Kanke T, Kawagoe J. Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 2003; 111 (1): 35-41.
47. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL, Morelli A, Cirino G. Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci USA 2001; 98 (24): 13936-13941.
48. Fozard JR, McCarthy C. Adenosine receptor ligands as potential therapeutics in asthma. Curr Opin Investig Drugs 2002; 3 (1): 69-77.
49. Fozard JR, Ellis KM, Villela Dantas MF, Tigani B, Mazzoni L. Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. Eur J Pharmacol 2002; 438 (3): 183-188.
50. Franco R, Casado V, Cortes A, Ferrada C, Mallol J, Woods A, Lluis C, Canela EI, Ferre S. Basic concepts in G-protein-coupled receptor homo-and heterodimerization. Sci World J 2007; 7: 48-57.
51. Gabriel D, Vernier M, Pfeifer MJ, Dasen B, Tenaillon L, Bouhelal R. High throughput screening technologies for direct cyclic AMP measurement. Assay Drug Dev Technol 2003; 1 (2): 291-303.
52. Gaillard I, Rouquier S, Giorgi D. Olfactory receptors. Cell Mol Life Sci 2004; 61 (4): 456-469.
53. Galitzky J, Reverte M, Carpene C, Lafontan M, Berlan M. Beta 3-adrenoceptors in dog adipose tissue: studies on their involvement in the lipomobilizing effect of catecholamines. J Pharmacol Exp Ther 1993; 266 (1): 358-366.
54. Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, Borea PA. The A3 adenosine receptor: an enigmatic player in cell biology. Pharmacol Ther 2008; 117 (1): 123-140.
55. Ghorbani M, Claus TH, Himms-Hagen J. Hypertrophy of brown adipocytes in brown and white adipose tissues and reversal of diet-induced obesity in rats treated with a beta3-adrenoceptor agonist. Biochem Pharmacol 1997; 54 (1): 121-131.
56. Gladue RP, Zwillich SH, Clucas AT, Brown MF. CCR1 antagonists for the treatment of autoimmune diseases. Curr Opin Investig Drugs 2004; 5 (5): 499-504.
57. Goncharova LB, Tarakanov AO. Why chemokines are cytokines while their receptors are not cytokine ones? Curr Med Chem 2008; 15 (13): 1297-1304.
58. Gosens R, Zaagsma J, Grootte Bromhaar M, Nelemans A, Meurs H. Acetylcholine: a novel regulator of airway smooth muscle remodelling? Eur J Pharmacol 2004; 500 (1-3): 193-201.
59. Gosens R, Zaagsma J, Meurs H, Halayko AJ. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 2006; 7: 73.
60. Gravanis A, Margioris AN. The corticotropin-releasing factor (CRF) family of neuropeptides in inflammation: potential therapeutic applications. Curr Med Chem 2005; 12 (13): 1503-1512.
61. Grbic DM, Degagne E, Langlois C, Dupuis AA, Gendron FP. Intestinal inflammation increases the expression of the P2Y6 receptor on epithelial cells and the release of CXC chemokine ligand 8 by UDP. J Immunol 2008; 180 (4): 2659-2668.
62. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005; 23: 821-852.
63. Halatchev IG, Ellacott KL, Fan W, Cone RD. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 2004; 145 (6): 2585-2590.
64. Hansen MJ, Jovanovska V, Morris MJ. Adaptive responses in hypothalamic neuropeptide Y in the face of prolonged high-fat feeding in the rat. J Neurochem 2004; 88 (4): 909-916.
65. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008; 117 (2): 207-231.
66. Ho WZ, Kaufman D, Uvaydova M, Douglas SD. Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J Neuroimmunol 1996; 71 (1-2): 73-80.
67. Holenz J, Merce R, Diaz JL, Guitart X, Codony X, Dordal A, Romero G, Torrens A, Mas J, Andaluz B, Hernandez S, Monroy X, Sanchez E, Hernandez E, Perez R, Cubi R, Sanfeliu O, Buschmann H. Medicinal chemistry driven approaches toward novel and selective serotonin 5-HT6 receptor ligands. J Med Chem 2005; 48 (6): 1781-1795.
68. Horga A, Montalban X. FTY720 (fingolimod) for relapsing multiple sclerosis. Expert Rev Neurother 2008; 8 (5): 699-714.
69. Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997; 88 (1): 131-141.
70. Ichinose M, Barnes PJ. Inhibitory histamine H3-receptors on cholinergic nerves in human airways. Eur J Pharmacol 1989; 163 (2-3): 383-386.
71. Ilnytska O, Argyropoulos G. The role of the agouti-related protein in energy balance regulation. Cell Mol Life Sci 2008; 65 (17): 2721-2731.
72. Jakubik J, Bacakova L, el-Fakahany EE, Tucek S. Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. J Pharmacol Exp Ther 1995; 274 (3): 1077-1083.
73. Jakubik J, Bacakova L, El-Fakahany EE, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997; 52 (1): 172-179.
74. Jarjour NN, Calhoun WJ, Schwartz LB, Busse WW. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am Rev Respir Dis 1991; 144 (1): 83-87.
75. Jarosz PA. The effect of kappa opioid receptor antagonism on energy expenditure in the obese Zucker rat. Biol Res Nurs 2007; 8 (4): 294-299.
76. Johansson-Lindbom B, Agace WW. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol Rev 2007; 215: 226-242.
77. Jolly PS, Bektas M, Olivera A, Gonzalez-Espinosa C, Proia RL, Rivera J, Milstien S, Spiegel S. Transactivation of sphingosine-1-phosphate receptors by FcepsilonRI triggering is required for normal mast cell degranulation and chemotaxis. J Exp Med 2004; 199 (7): 959-970.
78. Kamiji MM, Inui A. Neuropeptide y receptor selective ligands in the treatment of obesity. Endocr Rev 2007; 28 (6): 664-684.
79. Keeble JE, Brain SD. A role for substance P in arthritis? Neurosci Lett 2004; 361 (1-3): 176-179.
80. Kela J, Salmi P, Rimondini-Giorgini R, Heilig M, Wahlestedt C. Behavioural analysis of melanin-concentrating hormone in rats: evidence for orexigenic and anxiolytic properties. Regul Pept 2003; 114 (2-3): 109-114.
81. Kim N, Luster AD. Regulation of immune cells by eicosanoid receptors. Sci World J 2007; 7: 1307-1328.
82. Kirchgessner AL. Orexins in the brain- gut axis. Endocr Rev 2002; 23 (1): 1-15.
83. Kirchgessner AL, Liu M. Orexin synthesis and response in the gut. Neuron 1999; 24 (4): 941-951.
84. Kitamura K, Singer WD, Star RA, Muallem S, Miller RT. Induction of inducible nitric-oxide synthase by the heterotrimeric G protein Galpha13. J Biol Chem 1996; 271 (13): 7412-7415.
85. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H. The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74 (4): 486-496.
86. Kobayashi T, Narumiya S. Function of prostanoid receptors: studies on knockout mice. Prostaglandins Other Lipid Mediat 2002; 68-69: 557-573.
87. Kolakowski LF Jr. GCRDb: a G-protein-coupled receptor database. Receptors Channels 1994; 2 (1): 1-7.
88. Kristiansen K. Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 2004; 103 (1): 21-80.
89. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 2007; 120 (9 Suppl 1): S18-S24; discussion S.
90. Le Y, Murphy PM, Wang JM. Formyl-peptide receptors revisited. Trends Immunol 2002; 23 (11): 541-548.
91. Leibowitz SF, Weiss GF, Walsh UA, Viswanath D. Medial hypothalamic serotonin: role in circadian patterns of feeding and macronutrient selection. Brain Res 1989; 503 (1): 132-140.
92. Levin ER. Endothelins. N Engl J Med 1995; 333 (6): 356-363.
93. Levoye A, Dam J, Ayoub MA, Guillaume JL, Jockers R. Do orphan G-protein-coupled receptors have ligand-independent functions? New insights from receptor heterodimers. EMBO Rep 2006; 7 (11): 1094-1098.
94. Livingston M, Heaney LG, Ennis M. Adenosine, inflammation and asthma - a review. Inflamm Res 2004; 53 (5): 171-178.
95. Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78 (16): 8654-8662.
96. Maestroni GJ. Adrenergic modulation of dendritic cells function: relevance for the immune homeostasis. Curr Neurovasc Res 2005; 2 (2): 169-173.
97. Mall M, Gonska T, Thomas J, Hirtz S, Schreiber R, Kunzelmann K. Activation of ion secretion via proteinase-activated receptor-2 in human colon. Am J Physiol Gastrointest Liver Physiol 2002; 282 (2): G200-G210.
98. Magno F, Di Stefano A. Contribution of bronchial biopsies in the evaluation of pathogenesis and progression of COPD. Monaldi Arch Chest Dis 2007; 67 (4): 229-233.
99. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003; 15 (1): 23-32.
100. Marsh DJ, Weingarth DT, Novi DE, Chen HY, Trumbauer ME, Chen AS, Guan XM, Jiang MM, Feng Y, Camacho RE, Shen Z, Frazier EG, Yu H, Metzger JM, Kuca SJ, Shearman LP, Gopal-Truter S, MacNeil DJ, Strack AM, MacIntyre DE, Van der Ploeg LH, Qian S. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002; 99 (5): 3240-3245.
101. Massoumi R, Sjolander A. The role of leukotriene receptor signaling in inflammation and cancer. Sci World J 2007; 7: 1413-1421.
102. Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K. Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000; 276 (3): 905-908.
103. Mazzone SB. Targeting tachykinins for the treatment of obstructive airways disease. Treat Respir Med 2004; 3 (4): 201-216.
104. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW. Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. Am J Physiol Regul Integr Comp Physiol 2000; 279 (2): R695-R703.
105. Menard L, Ferguson SS, Zhang J, Lin FT, Lefkowitz RJ, Caron MG, Barak LS. Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. Mol Pharmacol 1997; 51 (5): 800-808.
106. Milia AF, Salis MB, Stacca T, Pinna A, Madeddu P, Trevisani M, Geppetti P, Emanueli C. Protease-activated receptor-2 stimulates angiogenesis and accelerates hemodynamic recovery in a mouse model of hindlimb ischemia. Circ Res 2002; 91 (4): 346-352.
107. Milligan G, Rees S. Chimaeric G alpha proteins: their potential use in drug discovery. Trends Pharmacol Sci 1999; 20 (3): 118-124.
108. Milligan G, Smith NJ. Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 2007; 28 (12): 615-620.
109. Milligan G, Ramsay D, Pascal G, Carrillo JJ. GPCR dimerisation. Life Sci 2003; 74 (2-3): 181-188.
110. Milligan G, Canals M, Pediani JD, Ellis J, Lopez-Gimenez JF. The role of GPCR dimerisation/oligomerisation in receptor signalling. Ernst Schering Found Symp Proc 2006 (2): 145-161.
111. Mohsenin A, Blackburn MR. Adenosine signaling in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2006; 12 (1): 54-59.
112. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, Videm V, Lappegard KT, Kohl J, Lambris JD. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002; 100 (5): 1869-1877.
113. Murris-Espin M, Pinelli E, Pipy B, Leophonte P, Didier A. Substance P and alveolar macrophages: effects on oxidative metabolism and eicosanoid production. Allergy 1995; 50 (4): 334-339.
114. Nagase I, Yoshida T, Kumamoto K, Umekawa T, Sakane N, Nikami H, Kawada T, Saito M. Expression of uncoupling protein in skeletal muscle and white fat of obese mice treated with thermogenic beta 3-adrenergic agonist. J Clin Invest 1996; 97 (12): 2898-2904.
115. Nett PC, Teixeira MM, Candinas D, Barton M. Recent developments on endothelin antagonists as immunomodulatory drugs - from infection to transplantation medicine. Recent Patents Cardiovasc Drug Discovery 2006; 1 (3): 265-276.
116. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002; 296 (5573): 1636-1639.
117. Nicosia S, Capra V, Rovati GE. Leukotrienes as mediators of asthma. Pulm Pharmacol Ther 2001; 14 (1): 3-19.
118. North RA. Molecular physiology of P2X receptors. Physiol Rev 2002; 82 (4): 1013-1067.
119. O'Connor BJ, Lecomte JM, Barnes PJ. Effect of an inhaled histamine H3-receptor agonist on airway responses to sodium metabisulphite in asthma. Br J Clin Pharmacol 1993; 35 (1): 55-57.
120. O'Hayre M, Salanga CL, Handel TM, Allen SJ. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 2008; 409 (3): 635-649.
121. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414 (6866): 916-920.
122. Okamoto Y, Ninomiya H, Tanioka M, Sakamoto A, Miwa S, Masaki T. Palmitoylation of human endothelin B. Its critical role in G protein coupling and a differential requirement for the cytoplasmic tail by G protein subtypes. J Biol Chem 1997; 272 (34): 21589-21596.
123. Omachi A, Ishioka K, Uozumi A, Kamikawa A, Toda C, Kimura K, Saito M. Beta3-adrenoceptor agonist AJ-9677 reduces body fat in obese beagles. Res Vet Sci 2007; 83 (1): 5-11.
124. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000; 289 (5480): 739-745.
125. Panaro MA, Mitolo V. Cellular responses to FMLP challenging: a mini-review. Immunopharmacol Immunotoxicol 1999; 21 (3): 397-419.
126. Pease JE. Asthma, allergy and chemokines. Curr Drug Targets 2006; 7 (1): 3-12.
127. Pease JE, Horuk R. CCR1 antagonists in clinical development. Expert Opin Investig Drugs 2005; 14 (7): 785-796.
128. Penela P, Ribas C, Mayor F Jr. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 2003; 15 (11): 973-981.
129. Pettipher R. The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses. Br J Pharmacol 2008; 153 (Suppl 1): S191-S199.
130. Pfleger KD, Eidne KA. Monitoring the formation of dynamic G-protein-coupled receptor-protein complexes in living cells. Biochem J 2005; 385 (Pt 3): 625-637.
131. Porter RA, Chan WN, Coulton S, Johns A, Hadley MS, Widdowson K, Jerman JC, Brough SJ, Coldwell M, Smart D, Jewitt F, Jeffrey P, Austin N. 1,3-Biarylureas as selective non-peptide antagonists of the orexin-1 receptor. Bioorg Med Chem Lett 2001; 11 (14): 1907-1910.
132. Premont RT, Gainetdinov RR. Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 2007; 69: 511-534.
133. Prieschl EE, Kulmburg PA, Baumruker T. The nomenclature of chemokines. Int Arch Allergy Immunol 1995; 107 (4): 475-483.
134. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, Ahuja SS. The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 2005; 83 (9): 672-681.
135. Raborn ES, Marciano-Cabral F, Buckley NE, Martin BR, Cabral GA. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB(2) receptor. J Neuroimmune Pharmacol 2008; 3 (2): 117-129.
136. Raddatz R, Schaffhauser H, Marino MJ. Allosteric approaches to the targeting of G-protein-coupled receptors for novel drug discovery: a critical assessment. Biochem Pharmacol 2007; 74 (3): 383-391.
137. Rambach G, Wurzner R, Speth C. Complement: an efficient sword of innate immunity. Contrib Microbiol 2008; 15: 78-100.
138. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007; 450 (7168): 383-387.
139. Rijnierse A, van Zijl KM, Koster AS, Nijkamp FP, Kraneveld AD. Beneficial effect of tachykinin NK1 receptor antagonism in the development of hapten-induced colitis in mice. Eur J Pharmacol 2006; 548 (1-3): 150-157.
140. Rossi M, Choi SJ, O'Shea D, Miyoshi T, Ghatei MA, Bloom SR. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 1997; 138 (1): 351-355.
141. Sawynok J. Adenosine receptor activation and nociception. Eur J Pharmacol 1998; 347 (1): 1-11.
142. Seeliger S, Derian CK, Vergnolle N, Bunnett NW, Nawroth R, Schmelz M, Von Der Weid PY, Buddenkotte J, Sunderkotter C, Metze D, Andrade-Gordon P, Harms E, Vestweber D, Luger TA, Steinhoff M. Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation i n vivo. FASEB J 2003; 17 (13): 1871-1885.
143. Sharma JN, Al-Dhalmawi GS. Bradykinin receptor antagonists: therapeutic implications. IDrugs 2003; 6 (6): 581-586.
144. Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K, Matsukura S. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 2002; 87 (1): 240-244.
145. Shimada M, Tritos NA, Lowell BB, Flier JS, Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998; 396 (6712): 670-674.
146. Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, Adawi M, Caspi D, Tishler M, Langevitz P, Rubinow A, Friedman J, Green L, Tanay A, Ochaion A, Cohen S, Kerns WD, Cohn I, Fishman-Furman S, Farbstein M, Yehuda SB, Fishman P. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. J Rheumatol 2008; 35 (1): 41-48.
147. Sodhi A, Biswas SK. fMLP-induced i n vitro nitric oxide production and its regulation in murine peritoneal macrophages. J Leukoc Biol 2002; 71 (2): 262-270.
148. Somers GR, Hammet FM, Trute L, Southey MC, Venter DJ. Expression of the P2Y6 purinergic receptor in human T cells infiltrating inflammatory bowel disease. Lab Invest 1998; 78 (11): 1375-1383.
149. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40 (6): 643-672.
150. Stutz AM, Morrison CD, Argyropoulos G. The Agouti-related protein and its role in energy homeostasis. Peptides 2005; 26 (10): 1771-1781.
151. Sun CX, Young HW, Molina JG, Volmer JB, Schnermann J, Blackburn MR. A protective role for the A1 adenosine receptor in adenosine-dependent pulmonary injury. J Clin Invest 2005; 115 (1): 35-43.
152. Sun CX, Zhong H, Mohsenin A, Morschl E, Chunn JL, Molina JG, Belardinelli L, Zeng D, Blackburn MR. Role of A2B adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J Clin Invest 2006; 116 (8): 2173-2182.
153. Sun Y, McGarrigle D, Huang XY. When a G protein-coupled receptor does not couple to a G protein. Mol Biosyst 2007a; 3 (12): 849-854.
154. Sun Y, Huang J, Xiang Y, Bastepe M, Juppner H, Kobilka BK, Zhang JJ, Huang XY. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J 2007b; 26 (1): 53-64.
155. Tecott LH, Sun LM, Akana SF, Strack AM, Lowenstein DH, Dallman MF, Julius D. Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors. Nature 1995; 374 (6522): 542-546.
156. Thurmond RL, Gelfand EW, Dunford PJ. The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines. Nat Rev Drug Discovery 2008; 7 (1): 41-53.
157. Townley RG. Interleukin 13 and the beta-adrenergic blockade theory of asthma revisited 40 years later. Ann Allergy Asthma Immunol 2007; 99 (3): 215-224.
158. Turner JE, Steinmetz OM, Stahl RA, Panzer U. Targeting of Th1-associated chemokine receptors CXCR3 and CCR5 as therapeutic strategy for inflammatory diseases. Mini Rev Med Chem 2007; 7 (11): 1089-1096.
159. Viola A, Luster AD. Chemokines and their receptors: drug targets in immunity and inflammation. Annu Rev Pharmacol Toxicol 2008; 48: 171-197.
160. von Wenckstern H, Zimmermann K, Kleuser B. The role of the lysophospholipid sphingosine 1-phosphate in immune cell biology. Arch Immunol Ther Exp (Warsz) 2006; 54 (4): 239-251.
161. Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J 2005; 19 (12): 1731-1733.
162. Warny M, Aboudola S, Robson SC, Sevigny J, Communi D, Soltoff SP, Kelly CP. P2Y(6) nucleotide receptor mediates monocyte interleukin-8 production in response to UDP or lipopolysaccharide. J Biol Chem 2001; 276 (28): 26051-26056.
163. Wheatley M, Hawtin SR. Glycosylation of G-protein-coupled receptors for hormones central to normal reproductive functioning: its occurrence and role. Hum Reprod Update 1999; 5 (4): 356-364.
164. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B. The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol 2001; 166 (12): 7172-7177.
165. Wren AM, Small CJ, Abbott CR, Dhillo WS, Seal LJ, Cohen MA, Batterham RL, Taheri S, Stanley SA, Ghatei MA, Bloom SR. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50 (11): 2540-2547.
166. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008; 153 (2): 263-270.
167. Xie GX, Palmer PP. How regulators of G protein signaling achieve selective regulation. J Mol Biol 2007; 366 (2): 349-365.
168. Yeomans MR, Gray RW. Opioid peptides and the control of human ingestive behaviour. Neurosci Biobehav Rev 2002; 26 (6): 713-728.
169. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F, Jeanrenaud B. Chronic intracerebroventricular neuropeptide-Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993; 133 (4): 1753-1758.
170. Zhang J, Frassetto A, Huang RR, Lao JZ, Pasternak A, Wang SP, Metzger JM, Strack AM, Fong TM, Chen RZ. The mu-opioid receptor subtype is required for the ano rectic effect of an opioid receptor antagonist. Eur J Pharmacol 2006; 545 (2-3): 147-152.
171. Zhang Z, Schluesener HJ. FTY720: a most promising immunosuppressant modulating immune cell functions. Mini Rev Med Chem 2007; 7 (8): 845-850.
172. Zheng Y, Voice JK, Kong Y, Goetzl EJ. Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes. FASEB J 2000; 14 (15): 2387-2389.
173. Zheng Y, Kong Y, Goetzl EJ. Lysophosphatidic acid receptor-selective effects on Jurkat T cell migration through a Matrigel model basement membrane. J Immunol 2001; 166 (4): 2317-2322.